Efficacy of doxazosin in specific hypertensive patient groups.
In practice, some of the major problems for the physician who treats hypertension are patients who are resistant to treatment or who have other complicating risk syndromes. Therefore the overall efficacy of an antihypertensive agent must include an assessment of effect in patients with serious ancillary problems. In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking. Doxazosin is particularly efficacious in many specific subgroups of patients with hypertension, and the results of relevant studies are discussed.
Taylor
S H
SH
University Department of Cardiovascular Studies, General Infirmary, Leeds, England.
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D017292:Doxazosin; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D010673:Pheochromocytoma / Q000188:drug therapy; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012907:Smoking; D014652:Vascular Diseases / Q000188:drug therapy
D000959:Antihypertensive Agents; D017292:Doxazosin; D011224:Prazosin